Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janbernd Kirschner

Showing results (81-90 of 173) with videos related to

Pageof 18
Sort By:
Neuromuscular Disorders : NMD|February 11, 2022
Corrigendum to 'Population pharmacokinetics-based recommendations for a single delayed or missed dose of nusinersen': Neuromuscular Disorders 31 (2021) 310-318/doi: 10.1016/j.nmd.2021.02.014Drew MacCannell, Zdenek Berger, Lilly East, et al.
Brain : a Journal of Neurology|December 23, 2025
Treatment evolution in spinal muscular atrophy: insights from the SMArtCARE registryCornelia Voigt-Müller, Michelle Pfaffenlehner, Günther Bernert, et al.
Neuropediatrics|December 1, 2021
Clinical and Genetic Aspects of Juvenile Onset Pompe DiseaseJohanna Holzwarth, Nadja Minopoli, Charlotte Pfrimmer, et al.
Der Nervenarzt|January 9, 2019
[Treatment evaluation in patients with 5q-associated spinal muscular atrophy : Real-world experience]Maggie C Walter, Bianca Dräger, Rene Günther, et al.
Journal of Neuromuscular Diseases|April 26, 2018
Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in GermanyAstrid Pechmann, Thorsten Langer, David Schorling, et al.
Neuromuscular Disorders : NMD|August 16, 2017
A comparative study of care practices for young boys with Duchenne muscular dystrophy between Japan and European countries: Implications of early diagnosisFumi Takeuchi, Hirofumi Komaki, Zentaro Yamagata, et al.
Frontiers in Pediatrics|November 30, 2023
High-sensitive cardiac troponin I (hs-cTnI) concentrations in newborns diagnosed with spinal muscular atrophyJessika Johannsen, Deike Weiss, Joenna Driemeyer, et al.
Journal of Neurology|February 9, 2017
Predictors of Health-Related Quality of Life in boys with Duchenne muscular dystrophy from six European countriesChristiane Otto, Birgit F Steffensen, Ann-Lisbeth Højberg, et al.
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|August 9, 2020
European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophyJanbernd Kirschner, Nina Butoianu, Nathalie Goemans, et al.
Journal of Comparative Effectiveness Research|August 16, 2019
Ataluren use in patients with nonsense mutation Duchenne muscular dystrophy: patient demographics and characteristics from the STRIDE RegistryFrancesco Muntoni, Isabelle Desguerre, Michela Guglieri, et al.
Pageof 18

Showing results (81-90 of 173) with videos related to

Sort By:
Pageof 18
Neuromuscular Disorders : NMD|February 11, 2022
Corrigendum to 'Population pharmacokinetics-based recommendations for a single delayed or missed dose of nusinersen': Neuromuscular Disorders 31 (2021) 310-318/doi: 10.1016/j.nmd.2021.02.014Drew MacCannell, Zdenek Berger, Lilly East, et al.
Brain : a Journal of Neurology|December 23, 2025
Treatment evolution in spinal muscular atrophy: insights from the SMArtCARE registryCornelia Voigt-Müller, Michelle Pfaffenlehner, Günther Bernert, et al.
Neuropediatrics|December 1, 2021
Clinical and Genetic Aspects of Juvenile Onset Pompe DiseaseJohanna Holzwarth, Nadja Minopoli, Charlotte Pfrimmer, et al.
Der Nervenarzt|January 9, 2019
[Treatment evaluation in patients with 5q-associated spinal muscular atrophy : Real-world experience]Maggie C Walter, Bianca Dräger, Rene Günther, et al.
Journal of Neuromuscular Diseases|April 26, 2018
Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in GermanyAstrid Pechmann, Thorsten Langer, David Schorling, et al.
Neuromuscular Disorders : NMD|August 16, 2017
A comparative study of care practices for young boys with Duchenne muscular dystrophy between Japan and European countries: Implications of early diagnosisFumi Takeuchi, Hirofumi Komaki, Zentaro Yamagata, et al.
Frontiers in Pediatrics|November 30, 2023
High-sensitive cardiac troponin I (hs-cTnI) concentrations in newborns diagnosed with spinal muscular atrophyJessika Johannsen, Deike Weiss, Joenna Driemeyer, et al.
Journal of Neurology|February 9, 2017
Predictors of Health-Related Quality of Life in boys with Duchenne muscular dystrophy from six European countriesChristiane Otto, Birgit F Steffensen, Ann-Lisbeth Højberg, et al.
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|August 9, 2020
European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophyJanbernd Kirschner, Nina Butoianu, Nathalie Goemans, et al.
Journal of Comparative Effectiveness Research|August 16, 2019
Ataluren use in patients with nonsense mutation Duchenne muscular dystrophy: patient demographics and characteristics from the STRIDE RegistryFrancesco Muntoni, Isabelle Desguerre, Michela Guglieri, et al.
Pageof 18